Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.70 |
| ▸ | AKR1B1 | P15121 | 16/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2007355 | 0.90 | PTGDR2 (0.74) | PTGDR2AKR1B1 | |
| SCHEMBL2006672 | 0.89 | PTGDR2 (0.75) | PTGDR2AKR1B1P2RX7PLA2G1BPLA2G2A | |
| SCHEMBL2010331 | 0.86 | PTGDR2 (0.67) | PTGDR2AKR1B1PLA2G1BPLA2G2A | |
| SCHEMBL2002085 | 0.84 | PTGDR2 (0.70) | PTGDR2AKR1B1 | |
| SCHEMBL2000681 | 0.84 | PTGDR2 (0.79) | PTGDR2AKR1B1 | |
| SCHEMBL2001831 | 0.84 | PTGDR2 (0.79) | PTGDR2AKR1B1PLA2G1BPLA2G2A | |
| SCHEMBL27790170 | 0.83 | PTGDR2 (0.50) | PTGDR2AKR1B1P2RX7 | |
| SCHEMBL2005637 | 0.82 | PTGDR2 (1.00) | PTGDR2AKR1B1P2RX7PLA2G1BPLA2G2A | |
| SCHEMBL2003155 | 0.82 | PTGDR2 (0.75) | PTGDR2AKR1B1PLA2G1BPLA2G2A | |
| SCHEMBL2007317 | 0.80 | PTGDR2 (0.73) | PTGDR2AKR1B1PLA2G1BPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| CN-102850324-A | Indole compounds | MICROBIA INC | 2013-01-02 | — | — | CN | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| EP-2049520-A2 | INDOLE COMPOUNDS | Ironwood Pharmaceuticals, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-1931632-A2 | USEFUL INDOLE COMPOUNDS | Microbia Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008019357-A2 | INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| US-20070203209-A1 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007022501-A2 | USEFUL INDOLE COMPOUNDS | MICROBIA, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203209-A1 | Useful indole compounds | TPH2, HRH2, HRH1 | PTGDR2 28/4885AKR1B1 1466/4885P2RX7 875/4885 |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | FAAH, FAAH2, AANAT | PTGDR2 157/4885AKR1B1 696/4885P2RX7 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.